This article considers the raison d'être for the use of low-dose statins, their safety, efficacy and potential as non-prescription drugs. It is very much a personal contribution to a controversial area which has become very topical.
Leader. Don't restrict heart drugs to those who can pay for them. The Independent 13 May 2004.
2.
Editorial.OTC statins: a bad decision for public health. Lancet2004 ; 363:1659.
3.
Law MR, Wald NJ, Rudnicka ARQuantifying effects of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ2003;326:1423.
4.
Heart Protection StudyCollaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360:7-22.
5.
Saku K., Sasaki J., Arakawa K.Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolaemia. Clin Ther1989;11:247-57.
6.
Lepre F., Nestel I., Clifton P., Lloyd B., Morgan T.Low-dose simvastatin in the treatment of mild to moderate hypercholesterolaemia . Clin Drug Invest1997;13:237-41.
7.
Mabuchi H., Kita T., Matsuzaki M. et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-doses simvastatin therapy in Japanese patients with hypercholesterolaemia and coronary heart disease. Circ J2002;66:1096-100.
8.
Farmer JALearning from the cerivastatin experience. Lancet2001;358: 1383-5.
9.
Thompson PD, Clarkson P., Karas RHStatin-associated myopathy. JAMA2003 ;289:1681-90.
10.
Parra JL, Reddy KRHepatotoxicity of hypolipidemic drugs. Clin Liver Dis2003;7:415-33.
11.
Omar MA, Wilson JPFDA adverse event reports on statin-associated rhabdomyolysis. Pharmacother2002;36:288-95.
12.
Martin J., Krum H.Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant?Drug Saf2003 ; 26:13-21.
13.
Stein EA, Davidson MH, Dujovne CA et al. Efficacy and safety of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J Cardiovasc Pharmacol Ther1996;1:107-16.
14.
Vega GL, Ma PTS, Cater NB et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol2003;91:956-60.
15.
Nutescu EA, Shapiro NLEzetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy2003;23:1463-74.
16.
Davidson MH , McGarry T., Bettis R. et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolaemia. J Am Coll Cardiol2002;40:2125-34.
17.
Cannon CP, Braunwald E., McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med2004 ;350:1495-504.
18.
Williams B. , Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ2004;328:634-40.
19.
Shepherd J.Statins for primary prevention: strategic options to save lives and money. J R Soc Med2004;97:66-71.
